ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 238 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2021. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $369,000 | -11.5% | 5,081 | +2.5% | 0.02% | -8.7% |
Q4 2021 | $417,000 | -2.8% | 4,956 | +4.3% | 0.02% | -11.5% |
Q3 2021 | $429,000 | -5.5% | 4,752 | -0.1% | 0.03% | -7.1% |
Q2 2021 | $454,000 | -30.9% | 4,757 | +0.2% | 0.03% | -37.8% |
Q4 2020 | $657,000 | – | 4,749 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |